quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:33:54·35d
SECFiling
Humacyte Inc. logo

Humacyte Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

HUMA· Humacyte Inc.
Health Care
Original source

Companies

  • HUMA
    Humacyte Inc.
    Health Care

Recent analyst ratings

  • Aug 27UpdateBarclays$3.50
  • May 14UpdateH.C. Wainwright$4.00
  • Dec 20UpdateH.C. Wainwright$15.00
  • Dec 11UpdateH.C. Wainwright$6.00
  • Aug 14UpdatePiper Sandler$3.50
  • Jun 22UpdateCantor Fitzgerald$6.00

Related

  • PR1d
    Humacyte Appoints Jim Mercadante as Chief Commercial Officer
  • PR2d
    Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair
  • SEC6d
    SEC Form PRE 14A filed by Humacyte Inc.
  • SEC27d
    SEC Form 10-K filed by Humacyte Inc.
  • PR27d
    Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
  • PR28d
    Humacyte Appoints Rick McElheny as Senior Vice President of Business Development
  • SEC30d
    Amendment: SEC Form SCHEDULE 13D/A filed by Humacyte Inc.
  • PR31d
    Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022